Related references
Note: Only part of the references are listed.COVID-19 Vaccine Response in People with Multiple Sclerosis
Emma C. Tallantyre et al.
ANNALS OF NEUROLOGY (2022)
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Yes
Leoni Rolfes et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria P. Sormani et al.
ANNALS OF NEUROLOGY (2021)
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Steve Simpson-Yap et al.
NEUROLOGY (2021)
Efficacy classification of modern therapies in multiple sclerosis
Imtiaz A. Samjoo et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases
Alexandre Avouac et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis et al.
NATURE MEDICINE (2021)
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
Livnat Brill et al.
JAMA NEUROLOGY (2021)
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Gustavo Luna et al.
JAMA NEUROLOGY (2020)
Immunological consequences of immune reconstitution therapy in multiple sclerosis: A systematic review
Johann Sellner et al.
AUTOIMMUNITY REVIEWS (2020)
P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions
T. Derfuss et al.
CLINICAL NEUROPHYSIOLOGY (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study
Amit Bar-Or et al.
NEUROLOGY (2020)
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
David Baker et al.
JAMA NEUROLOGY (2017)
Both cladribine and alemtuzumab may effect MS via B-cell depletion
David Baker et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial
Clifton O. Bingham et al.
ARTHRITIS AND RHEUMATISM (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)